Navigation
banner

Cancer Therapeutics & Partnering Summit

2017-11-182018-05-282018-04-28
EARLY BIRD DISCOUNT! Register by Apr 28, 2018 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 speaker list is currently being formed.

Please come back and visit this page for update.

BELOW ARE THE SPEAKERS FROM 2017

PLENARY KEYNOTE SPEAKERS
Joydeep Goswami

Joydeep Goswami
President, Clinical NGS & Oncology Division
Thermo Fisher Scientific
Joydeep Goswami
President, Clinical NGS & Oncology Division
Thermo Fisher Scientific
 
About Speaker:

Joydeep Goswami has been President, Clinical Next Generation Sequencing and Oncology Division (CSD) since July 2016. CSD is focused on serving the targeted sequencing needs of customers in research and clinical applications, with an emphasis on oncology. Prior to his current role, Joydeep held various executive positions leading global businesses including Protein & Cell Analysis, Stem Cells and Regenerative Medicine and leading Life Technologies’ businesses in Japan and Asia. Before joining Thermo Fisher through the acquisition of Life Technologies, Joydeep worked at McKinsey & Company.

Joydeep has a Ph.D. and M.S. in Chemical Engineering from Massachusetts Institute of Technology, an M.B.A. from MIT Sloan School of Management. He holds a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology.

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

Razelle Kurzrock

Razelle Kurzrock
Senior Deputy Center Director, Moores Cancer Center
UC San Diego, Moores Cancer Center
Razelle Kurzrock
Senior Deputy Center Director, Moores Cancer Center
UC San Diego, Moores Cancer Center
 
About Speaker:

Razelle Kurzrock, MD
Senior Deputy Center Director
Director, Center for Personalized Cancer Therapy
Director, Clinical Trials Office
Director, Rare Tumor Clinic
Team Leader, Experimental Therapeutics
UCSD Moores Cancer Center
Chief, Division of Hematology and Oncology
UC San Diego School of Medicine

Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.

At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine. Dr. Kurzrock received her MD degree from the University of Toronto and has over 650 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building.

Dr. Kurzrock also has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.

Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.

Laszlo Radvanyi

Laszlo Radvanyi
Senior Vice President, Senior Global Scientific Advisor – Immunology, Immuno-Oncology
EMD Serono R&D Institute
Laszlo Radvanyi
Senior Vice President, Senior Global Scientific Advisor – Immunology, Immuno-Oncology
EMD Serono R&D Institute
 
About Speaker:

Laszlo Radvanyi earned his Ph.D. degree in Clinical Biochemistry in 1996 at the University of Toronto, Toronto, Canada performing his thesis work on T-cell immunology. Dr. Radvanyi (Laszlo) joined EMD Serono (Merck KGaA, Darmstadt, Germany) in November 2015 as Senior Vice President (SVP), Global Head of the Immuno-Oncology Translational Innovation Platform (TIP) where he oversaw the day-to-day research operations in immuno-oncology at the company for 1.5 years. Laszlo’s key role coming into this position was to perform a much-needed rebuilding and re-organization of the Immuno-Oncology TIP as well as re-focusing and pruning the pipeline. He doubled the size of the TIP within this time period hiring key talent and restructured the organization establishing key human tumor immunology research areas and addressing key gaps in the pipeline in immune costimulation and the targeting of new tumor immune suppressive pathways. Laszlo also spearheaded a number of new company partnerships in key immuno-oncology areas, such as a deal with Domain Therapeutics (Strasbourg, France) in the adenosine receptor antagonist space, and a large deal with F-Star (Cambridge, UK) bringing in a new bispecific IND-enabled molecule targeting PD-L1 and Lag3. He also established academic alliances in the biomarker space, such as a comprehensive alliance with MD Anderson Cancer Center focusing on biomarker-driven clinical trials on key EMD Serono immuno-oncology pipeline assets. In May 2017, Laszlo transitioned to a more strategic role at EMD Serono as the Global Senior Scientific Advisor in Immuno-Oncology and Immunology where he plays a central scientific advisory role for all immuno-oncology and immunology programs, develops major academic center alliances, participates in a team developing new combination immunotherapy opportunities with avelumab (anti-PD-L1) as part of EMD Serono’s alliance with Pfizer in this area, and works on core team developing key scientific leadership strategies within EMD Serono/Merck KGaA.

Prior to joining EMD Serono, Laszlo was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center in Houston for about 10 years. While at M.D. Anderson, he established a GMP-grade T-cell therapy manufacturing program for metastatic melanoma using expanded tumor-infiltrating lymphocytes (TIL) and performed basic research on TIL biology and effector function focusing on TNF-R family costimulation and CD8+ T-cell differentiation where he made new discoveries on the role of BTLA in T cells. Laszlo was co-PI or co-investigator on a number of TIL clinical trials testing new methods to augment TIL adoptive transfer therapeutic efficacy in metastatic melanoma, including development of retroviral gene T-cell transduction approaches. In addition to his work on TIL therapy and basic research, Laszlo was tasked to establish a new Immunomonitoring Core Facility as part of MD Anderson’s Cancer Center Support Grant infrastructure. He established and directed this facility for 8 years (2005-2013) hiring all the staff and running the day-to-day activities of the facility.

Between joining EMD Serono and leaving MD Anderson Cancer Center in 2014, Laszlo decided to diversity his activities into the biotechnology sector and helped start a biotechnology company to commercialize TIL therapy for melanoma and other cancers. He was the founding CSO for Lion Biotechnologies (recently renamed Iovance Therapeutics) for 1.5 years and designed and built the biotech’s 8,000 sq. ft. R&D facility at the University of South Florida’s Innovation Center in Tampa, FL. Laszlo oversaw the hiring of the research staff and lead research and development activities leading to two IND submissions in collaboration with Moffitt Cancer Center.

Laszlo has authored over 110 papers, has served on the advisory board of a number of pharma and biotech companies, reviewed for numerous journals in the tumor immunology space, and has sat on a number of national and international research grant review panels, including the NIH-NCI, NHLBI, CIHR, BioCanRx, and EU Framework Program (FP). He is on the Keystone Conferences Scientific Advisory Board, is on editorial board of the Journal of Immunotherapy for Cancer (JITC), and sits on the Industry Advisory Council of the Society for Immunotherapy of Cancer (SITC).

Oncology Partnering & Deal-Making 2017
DISTINGUISHED SPEAKERS
Michael Arciero

Michael Arciero
Director of Technology Licensing and New Ventures
USC Stevens Center for Innovation
Michael Arciero
Director of Technology Licensing and New Ventures
USC Stevens Center for Innovation
 
About Speaker:

Michael Arciero, J.D. is the Director of Technology Licensing and New Ventures at the USC Stevens Center for Innovation with over 15 years of experience in academic, foundation, and industry technology transfer. Most recently, Arciero was Interim Director of the University of California, Riverside (UCR) Office of Technology Commercialization where he worked closely with faculty, staff, and students to help identify and commercialize their research. Arciero led the UCR negotiation efforts with a large company which resulted in a significant increase in research funding and the closing of a new license agreement for the commercialization of key technology in the University’s intellectual property portfolio. Prior to UCR, Arciero was counsel for the E.O. Wilson Biodiversity Foundation, and served as a licensing attorney at Diversa Corporation (now BASF), where he focused on licensing the company’s industrial enzymes portfolio and supported the business development groups in monetizing access to their proprietary environmental sequence libraries.

Arciero started his career in biotechnology as a researcher at LXN Corporation (now Johnson & Johnson) where he worked on the development of the first portable diagnostic device for diabetes management that allowed patients to measure both blood glucose and glycated protein (fructosamine).

Arciero earned a Bachelor of Science in Biology from the University of California, San Diego and a J.D. from the University of San Diego School of Law. He is an active member of the Association of University Technology Managers, Licensing Executives Society, Biotechnology Industry Organization and Association of Strategic Alliance Professionals.

Suzanne Benedict

Suzanne Benedict
Vice President of Regulatory Affairs
TRACON Pharmaceuticals
Suzanne Benedict
Vice President of Regulatory Affairs
TRACON Pharmaceuticals
 
About Speaker:

Ms. Benedict joined TRACON Pharmaceuticals as the Director of Regulatory Affairs in 2007 and was promoted to Vice President of Regulatory Affairs in January 2014. Ms. Benedict previously held positions in Regulatory Chemistry, Manufacturing and Controls (CMC) at Pfizer, Inc. and Amylin Pharmaceuticals, Inc. At Pfizer, she led the Regulatory CMC activities for the approval of Viracept® Tablets, 625 mg and played a key role in the global approvals for Macugen®. She began her pharmaceutical career at Agouron Pharmaceuticals in Medicinal Chemistry synthesizing VEGF inhibitors. Ms. Benedict has led the Regulatory CMC activities on chemical and pharmaceutical development teams from compound identification through commercialization and has experience with small molecule, peptide, oligonucleotide and protein products spanning a wide range of therapeutic areas. Ms. Benedict received a B.A. from the University of California, Santa Barbara and a M.S. in Chemistry from San Diego State University.

Kathleen Denis

Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
 
About Speaker:

Managing the intellectual assets of The Rockefeller University in New York City, Dr. Denis works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the Board of Directors of the Association of University Technology Managers (AUTM), the Pennsylvania Biotechnology Association and is a former Chair of the Board of Governors of Certified Licensing Professionals, Inc. Specializing in the management of intellectual assets in the life sciences, she has worked with academic institutions and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses. Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in human genetics from University of Texas and an undergraduate degree in genetics from Cornell University.

Rubén Flores-Saaib

Rubén Flores-Saaib
Director of Commercialization
University of California, San Diego
Rubén Flores-Saaib
Director of Commercialization
University of California, San Diego
 
About Speaker:

Ruben earned his doctorate in chemistry and biochemistry at UCLA, and began his career in the San Diego biotechnology industry at BD Biosciences Pharmigen. He has held a variety of positions with increasing responsibility in R&D, marketing, business development and technology commercialization. His professional career also includes Biosite (now Inverness), where he helped design, initiate, negotiate and monitor clinical trials; and later joined Chemicon (now Millipore-Sigma), where he managed R&D, worldwide clinical-trial operations, and marketing activities for diagnostic products. While at Millipore-Sigma, Flores also created the world-wide Scientific Collaborations and Business Development group, tasked with working with academic partners across the globe for the development of early-stage academic research.

Most recently, Flores served as Vice President of Business Development and Technology Transfer for the Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center, where he focused on fostering the entrepreneurial ecosystem for startups in Los Angeles.

As Director of Commercialization, Flores oversees all aspects of licensing and company interactions, as well as programs to engage with industry and investment partners. .

Enoch Kariuki

Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
 
About Speaker:

Enoch is a Vice President at H.I.G. BioHealth Partners, where he focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. He joined Leerink from UBS where he was an Associate Director in the Global Healthcare Investment Banking Group. At Leerink and UBS, Enoch gained extensive experience advising healthcare companies across the biopharmaceutical, medical devices, diagnostics, healthcare services and information technology sectors on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

Previously, Enoch worked in the pharmaceutical industry as a Post-Doctoral Fellow in the R&D Strategy and Analytics group at Bristol-Myers Squibb and as a Pharmacist at CVS Caremark.

Enoch earned an M.B.A. from the Tuck School of Business at Dartmouth and a Doctor of Pharmacy degree from Texas Southern University.

Casie Kelly

Casie Kelly
Assistant Director of Licensing
University of California, Irvine
Casie Kelly
Assistant Director of Licensing
University of California, Irvine
 
About Speaker:

Casie Kelly is the Assistant Director, Licensing at UCI Applied Innovation, Invention Transfer Group. Casie works closely with faculty, staff, and students at UCI to help identify aspects of their research with commercial potential. Her responsibilities include evaluating new inventions, managing all aspects of patent prosecution within her portfolio of inventions, and licensing the university’s patent rights to both established companies and startups. Casie also oversees ITG’s operations group which is responsible for patent prosecution, invention intake, invention analysis, and post agreement compliance. Prior to joining UCI in 2012, Casie worked for six years at UCLA’s technology transfer office, where she managed a large portfolio of life science inventions. Casie is a named inventor on 9 issued US patents and previously developed therapeutic monoclonal antibodies that are in clinical development. Casie earned her Ph.D. in Microbiology & Molecular Genetics from Harvard University and B.S. degrees in Chemistry and in Microbiology from UCLA. Casie is a registered patent agent at the USPTO.

Alice Li

Alice Li
Executive Director, Center for Technology Licensing
Cornell University
Alice Li
Executive Director, Center for Technology Licensing
Cornell University
 
About Speaker:

Alice Li is the Executive Director of the Center for Technology Licensing (CTL) at Cornell University. She oversees all aspects of technology management, marketing, license negotiation, outreach, and CTL activities to facilitate new venture creation in its services to all Cornell campuses and colleges.

Reflective of its broad research endeavors, Cornell’s inventions range from disciplines such as chemistry, engineering, information technologies, and material science, to medicine, plant science, and veterinary medicine.

Alice has 14 years of experience in university technology transfer. She was the Director of Licensing of the Ithaca office from 2011 to 2014, providing mentorship for licensing professionals in intellectual property protection, license negotiation, and spearheading new commercialization initiatives. Alice joined CTL in 2002 and started with hands-on management of invention portfolios, negotiations of complex deals and engagement with startup companies.

Prior to joining CTL, Alice was an R&D manager at BioArray Solutions, a NJ biotech company in diagnostic and drug discovery. During her five-year tenure there, the company grew from a two-person startup to an enterprise of fifty people. BioArray Solutions was acquired by a publicly traded company in 2008.

Alice obtained her Ph.D. from Cornell University and B.S. from Tsinghua University. She is also an inventor and patent holder. Alice has been a Certified Licensing Professional since 2010.

Casey Logan

Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
 
About Speaker:

Mr. Logan joined TRACON as Chief Business Officer in February 2013. Prior to joining TRACON, Mr. Logan led corporate development efforts at RuiYi, Inc. (formerly Anaphore) including establishment of the company’s operations in Shanghai, China. From 2007 to 2010, Mr. Logan led corporate development and strategic planning efforts at Anadys Pharmaceuticals (acquired by Roche). From 2001 to 2007, he was with Eli Lilly and Company in Indianapolis, IN, in the corporate business development group. During his career, Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two startup companies. Prior to Lilly, Mr. Logan was an officer in the US Naval Nuclear Propulsion Program. Mr. Logan received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S.E. in Chemical Engineering from the University of Michigan.

Chris Meda

Chris Meda
Chief Business Officer
IncellDx
Chris Meda
Chief Business Officer
IncellDx
 
About Speaker:

Ms. Meda, currently CBO at IncellDx, has 30 years of leadership in the global diagnostic and pharmaceutical industries. Her management responsibilities have ranged from VP to President to CEO where she created worldwide strategic business direction and plans, operations and commercialization of more than 30 products for various disease areas at Hoffman-LaRoche, Schering AG pharmaceuticals, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics. She is CBO at IncellDx, a single cell diagnostic company focused on multiplex RNA in situ Hybridization, multiplex Protein Detection, DNA/Cell Cycle, simultaneously detection in Every Cell. She is National Chair of Women in BIO-Sponsorship, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and, a Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Prior to IncellDx, Ms. Meda was President of Response Genetics (RGI), a precision medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers which help medical oncologists with therapeutic treatment decisions for patients with these cancer types. Prior to RGI, she was CEO, President at Arcxis Biotechnologies a venture backed start-up with a focus on molecular diagnostic extraction devices and reagents. Arcxis was sold to Fluidigm in September, 2010. At Hoffman-LaRoche, Chris was VP of the Roche Molecular Diagnostics Division for the Global Women’s Health and subsequently became Vice President of Business Development. Her leadership role and portfolio responsibilities included global strategic planning for the portfolio, oversight of research and development and the commercialization of PCR-based diagnostics for Human Papillomavirus, Chlamydia, Herpes Simplex Virus and Group B Streptococcus. Her business development role was focused on companion diagnostics where she completed agreements between Roche Molecular Diagnostics and four pharmaceutical companies.

Michael Meyers

Michael Meyers
Managing Director, Head of Investment Banking
TR Winston
Michael Meyers
Managing Director, Head of Investment Banking
TR Winston
 
About Speaker:

Michael Meyers is Managing Director and Head of Investment Banking at T.R. Winston & Company, with over 25 years of experience in investment banking, venture capital and asset management. Mr. Meyers is responsible for originating and managing T.R. Winston’s venture capital and strategic advisory businesses, with an emphasis in healthcare; as well as technology and retail/consumer. Meyers also serves as Interim CEO of Cell Biotherapy, an immuno-oncology company that was founded with leading researchers and clinicians from Keck and Norris Comprehensive Cancer Center at USC, and Tivorsan Pharmaceuticals, a neuromuscular rare disease company.

Prior to joining T.R. Winston, Meyers was CEO of Arcoda Capital Management LP, a healthcare focused fund. Meyers was also a Partner and Portfolio Manager with GoldenTree Asset Management, a $22 billion asset management firm. Between 2002 and 2006, Mr. Meyers was a founding Partner and Portfolio Manager with Trivium Capital Management. Meyers has also served as a Managing Director and Partner of Global Biomedical Partners, a life sciences venture capital firm located in New York and Zurich, Switzerland, that was acquired by HBM Bioventures in 2003.

Meyers has also served as Director of Biotechnology and Pharmaceutical Investment Banking with Merrill Lynch & Co. Meyers began his career as a Biotechnology and Medical Device Research Associate at Hambrecht & Quist.

Meyers serves on the Board of Trustees of the Ronald Reagan UCLA Medical Center, the Board of Councilors of the University of Southern California’s School of Dramatic Arts, and Stevens Center for Innovation, and as a Trustee of The JED Foundation.

Meyers received an M.P.H. in Health Policy & Management from Columbia University, and an A.B. in Biology from Brandeis University

Aaron Miscenich

Aaron Miscenich
President
New Orleans BioInnovation Center
Aaron Miscenich
President
New Orleans BioInnovation Center
 
About Speaker:

Aaron Miscenich has been the President & CEO of the New Orleans BioInnovation Center since 2004.  With an emphasis on entrepreneurship in the life sciences, the BioInnovation Center is a $48 million LEED Gold business incubator, focused primarily on the local commercialization of university technologies.

Aaron Miscenich also manages New Orleans BioFund, a $2.4 million evergreen capital source for the regional life science industry. Miscenich oversees the fund’s activity in equity investments, alternative finance/mezzanine lending, and senior debt transactions for start-ups and emerging companies.

From 2011 to 2015 Miscenich was selected to serve as interim Executive Director of the Louisiana Cancer Research Center (LCRC), a New Orleans-based research collaborative between LSU Health Science Center, Tulane University, Xavier University, and the Ochsner Health System.  With the mission of establishing the first National Cancer Institute designated institution in Louisiana, the LCRC now operates from a 170,000 square foot laboratory facility in the heart of the New Orleans' downtown research and clinical community. 

Miscenich is currently the Chairperson of LouisianaBIO, the state affiliation the Biotechnology Industry Organization (BIO) and serves on the board of the Association of University Research Parks (AURP).

Miscenich holds a B.S. in Physics with a minor in Mathematics from the University of New Mexico and an M.B.A. in Finance and General Management from Tulane University.

Greg Naeve

Gregory Naeve
Chief Business Officer
Bellicum Pharmaceuticals
Gregory Naeve
Chief Business Officer
Bellicum Pharmaceuticals
 
About Speaker:
Panna Sharma

Panna Sharma
CEO and President
Cancer Genetics, Inc.
Panna Sharma
CEO and President
Cancer Genetics, Inc.
 
About Speaker:

Mr. Sharma became a member of our board of directors and our Chief Executive Officer in May of 2010. Mr. Sharma was at TSG Partners, a specialty life sciences consultancy and advisory company, from 2001 to 2010, where he was the Managing Partner and founder. At TSG he led the development of strategic initiatives, corporate growth strategy and corporate turnarounds for both public and private companies. He also led over 70 buy and sell-side transactions for life sciences, healthcare and biopharma companies. At TSG, he established the Global Diagnostics Index, the Global Biotools Index and several other life science capital markets indices that are still used in the life science industry. Prior to founding TSG, Mr. Sharma was the Chief Strategy Officer for iXL Enterprises, Inc. (“iXL”), a public e-business consultancy where he led strategy development and acquisitions activity and was part of the management team that aided in taking the company public in June 1999. At iXL, he also managed the specialty e-business strategy practices group that grew from under $4 million in revenue in 1998 to over $75 million in 2000. From 1996 to 1998, Mr. Sharma was a partner at Interactive Solutions, Inc., a marketing and strategy consultancy focused on health care and financial services in Cambridge, Massachusetts, that was sold to Omnicom, Inc., one of the largest global market analysis and marketing companies. Prior to that time, Mr. Sharma served as a consultant to Putnam Investment Management, LLC and Bank of America Corporation. Mr. Sharma has also served on the board of directors of EpicEdge, a health care and government focused IT services firm, from 2001 to 2003 and as chairman of the Advisory Board for EndoChoice, a global leader for the gastrointestinal treatment market from 2008 to 2010. Mr. Sharma attended Boston University from 1987 to 1992 in the University Professor’s Program.

Igor	Stagljar

Igor Stagljar
Professor, Donnelly Centre, Department of Molecular Genetics, Department of Biochemistry
University of Toronto
Igor Stagljar
Professor, Donnelly Centre, Department of Molecular Genetics, Department of Biochemistry
University of Toronto
 
About Speaker:

Igor Stagljar is a highly-accomplished mid-career scientist and a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre in the University of Toronto, Canada. He received his Ph.D. in Molecular Biology from ETH Zurich in Switzerland. His postdoctoral fellowship was at the University of Zurich, where he studied RNA transcription and DNA repair. In addition, Igor was a visiting scientist at the University of Washington in Seattle with Stan Fields, the inventor of the yeast two-hybrid technology. Igor was Assistant Professor at the University of Zurich from 2002-2005, Associate Professor at the University of Toronto since 2005, and Professor since 2010. Amongst his most significant scientific achievements to date are the elucidation of functions of various membrane proteins involved in human health and disease. He is currently involved in major proteomics projects to map how integral membrane proteins interact to produce either healthy or diseased cells. To that end, his lab is using high-throughput interactive proteomics, genetic, and biochemical tools to understand how cell signaling and membrane transport pathways control cell behavior in normal and disease cells.

Igor is the author of more than 100 PubMed cited scientific papers and is the recipient of several national and international science awards, the most recent one being “The 2015 Inventor of the Year” award. He is a member of the Editorial Board of Journal of Molecular Biology, Molecular Systems Biology, BioTechniques, Molecular Genetics and Genomics, BMC Biotechnology, and Biochemical and Biophysical Research Communications (BBRC). Lastly, he is a co-founder of Dualsystems Biotech Inc., one of the world-leading companies in the field of interactive proteomics, and has recently co-founded a new Toronto-based biotech start-up company named “ProteinNetwork Therapeutix (PN-Tx)”.

Jill Stefanelli

Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
 
About Speaker:
Lesley Stolz

Lesley Stolz
Head of JLABS California
Johnson & Johnson Innovation
Lesley Stolz
Head of JLABS California
Johnson & Johnson Innovation
 
About Speaker:

Lesley Stolz, PhD, fosters Johnson & Johnson’s external R&D engine and supports the innovation community by leading the Johnson & Johnson Innovation, JLABS business on the West Coast. She has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. Previously, she was Senior Director of Transactions negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.

Charles Theuer

Charles Theuer
President and CEO
TRACON Pharmaceuticals
Charles Theuer
President and CEO
TRACON Pharmaceuticals
 
About Speaker:

Dr. Theuer joined TRACON as its President and Chief Executive Officer, and a member of its board of directors, in July 2006. Previously, Dr. Theuer was Chief Medical Officer at TargeGen Inc, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer led the clinical development of Sutent® (sunitinib maleate) in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January, 2006 for treating advanced kidney cancer. Dr. Theuer also held senior positions at IDEC Pharmaceuticals, where he contributed to the clinical development of Rituxan® and Zevalin®, and the National Cancer Institute. Dr. Theuer holds a B.S. degree from MIT, M.D. degree from UC San Francisco and Ph.D. degree from UC Irvine. He completed a residency in general surgery at Harbor-UCLA Medical Center. Dr. Theuer held academic positions at the National Cancer Institute and at UC Irvine, where he was a member of the Division of Surgical Oncology. He is currently an Associate Clinical Professor in the Division of Epidemiology, Department of Medicine, at UC Irvine. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients as well as cancer epidemiology.

Cancer Immunotherapy 2017
DISTINGUISHED SPEAKERS
Alan Epstein

Alan Epstein
Professor of Pathology
Keck School of Medicine of USC
Alan Epstein
Professor of Pathology
Keck School of Medicine of USC
 
About Speaker:

Alan Epstein received his bachelors degree from Wesleyan University and his MD/PhD degrees from Stanford University School of Medicine. His research focuses on various aspects of tumor biology but most recently, on the development of reagents for the immunotherapy of cancer. In addition, his laboratory is involved in elucidating the host/tumor interaction including the induction and function of suppressor cell populations and methods to reverse their activity in cancer. Over a 34 year career, he has developed several antibodies for the treatment of cancer including Lym-1 for lymphoma therapy and Tumor Necrosis Antibodies that target necrosis in cancer lesions. In addition, he has generated a number of diagnostic antibodies including a human myeloid derived suppressor cell clinical assay for the diagnosis and monitoring of cancer patients. His latest research interests are in the area of genetically engineered T cells for the treatment of solid tumors in patients. He has founded three biotechnology companies and has acted as a consultant to the industry in his field of expertise. Dr. Epstein has over 165 peer reviewed publications and 25 patents on reagents and methods for cancer immunotherapy.

Ulrich Ernst

Ulrich Ernst
Chief Operating Officer
Amunix
Ulrich Ernst
Chief Operating Officer
Amunix
 
About Speaker:

Ulrich Ernst, PhD is the Chief Operating Officer at Amunix. Dr. Ernst has previously held senior level positions with several global biopharmaceutical companies and brings over 25 years of experience in successfully moving products from clinical stage development to market approval. As VP/Site Head of Alexion’s commercial Rhode Island manufacturing facility, Dr. Ernst led the startup efforts to gain FDA, EMA and rest-of-world site approvals for SOLIRIS®. As Vice-President of Commercial Manufacturing at ZymoGenetics, Dr. Ernst helped create the infrastructure for the commercial manufacturing/medical device enterprise which launched the RECOTHROM® hemostasis franchise. Additionally, Dr. Ernst has held senior operations positions with JNJ and Baxter, where he contributed to the product development and global launches of NATRECOR® and ADVATE®, respectively. Dr. Ernst began his career at Regeneron and Somatogen where he contributed to development efforts on novel protein therapeutics. Dr. Ernst received a B.S. in Chemical Engineering from the University of Minnesota and a Ph.D. in Chemical Engineering from Lehigh University in Pennsylvania. Dr. Ernst is broadly published and is an inventor on several patents.

Napoleone Ferrara

Napoleone Ferrara
Distinguished Professor of Pathology
University of California, San Diego Moores Cancer Center
Napoleone Ferrara
Distinguished Professor of Pathology
University of California, San Diego Moores Cancer Center
 
About Speaker:

Dr. Ferrara earned his M.D. degree in 1981 from the University of Catania Medical School in Italy.  After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988.  It is there where he spent nearly 25 years working on the isolation, molecular cloning and biological characterization of  VEGF-A which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy.  His research also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders.  In December 2012, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology, Distinguished Adjunct Professor of Ophthalmology & Pharmacology, and Senior Deputy Director for Basic Science of the Moores Cancer Center.  He plans to continue his research focusing on the biology of angiogenesis and the identification of its regulators.  

Dr. Ferrara has authored over 300 scientific publications, which have been cited over 130,000 times according to Google Scholar.  He is also the recipient of numerous scientific awards, including the AACR Cain Memorial Award, the Lefoulon-Delalande-Institut de France Prize, the Passano Award, the General Motors Cancer Research Award, the ASCO Science of Oncology Award, the Pezcoller Foundation-AACR International Award, the Lasker-deBakey Clinical Medical Research Award, the Janssen Award for Biomedical Research, the Economist Innovation Award, the Breakthrough Prize in Life Sciences, the Antonio Champalimaud Vision Award and the Gairdner Foundation International Award.  Dr. Ferrara has been an elected member of the National Academy of Sciences, USA since 2006 and became an elected member of the National Academy of Medicine in 2015.

Thomas Kleen

Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
 
About Speaker:

Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis.  Prior he held the position of Director, Business and Technology Development and the function of Director, Assay Development and R&D at CTL, USA He received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany.  During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections.  He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematologic al disorders and malignancies after treatment with full myelo-ablative regimens (http://www.linkedin.com/in/thomasokleen).

His expertise is in the areas of immunology, vaccine and biologic evaluation, immunogenicity and oncology.  One focus is monitoring of Cell Mediated Immunity (CMI) and Bio-markers during immunotherapy, vaccine development and detection of adverse immune reactions during drug development.  He spends significant time educating pharmaceutical entities and governmental agencies about validated, standardized, GLP compliant technologies, which can be deployed today during pre-clinical and clinical trials, for sample logistics and immune monitoring.
Since 2009 Dr. Kleen is member of the SITC-FDA Task Force on Immunotherapy Biomarkers, which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.

Richard Kornbluth

Richard Kornbluth
President & Chief Scientific Officer
Multimeric Biotherapeutics
Richard Kornbluth
President & Chief Scientific Officer
Multimeric Biotherapeutics
 
About Speaker:

Richard S. Kornbluth, M.D., Ph.D. is President and Chief Scientific Officer of Multimeric Biotherapeutics, Inc., La Jolla, CA, and Professor at the Vaccine Research Institute of San Diego. He trained in tumor biology and immunology at Harvard and The Scripps Research Institute following which he moved to UC San Diego (UCSD) where he focused on HIV-macrophage interactions and HIV vaccines. While at UCSD as an Associate Professor of Medicine, he developed a novel technology for expressing TNF SuperFamily ligands as soluble, multi-trimer proteins. Multimeric Biotherapeutics was founded to develop this invention and the company has since been supported by grants and contracts from the NCI, NIAID, NIDA, NIDDK, and the DOD. Dr. Kornbluth received his A.B. from Harvard, M.D. from New York Medical College, and Ph.D. from Columbia University.

Yvonne Lin

Yvonne Lin
Medical Director, Product Development Oncology
Genentech-Roche
Yvonne Lin
Medical Director, Product Development Oncology
Genentech-Roche
 
About Speaker:

Yvonne Lin, MD, MS is a Medical Director in Product Development, Oncology at Genentech-Roche. Her current research focuses on cancer immunotherapy, particularly as it applies to gynecologic malignancies including ovarian and uterine cancers. Prior to joining Genentech, Yvonne was a physician-scientist and assistant professor of gynecologic oncology and obstetrics and gynecology at the University of Southern California. As an NCI K08-funded investigator, she studied the effects of endoplasmic reticular stress on endometrial cancer development and potential opportunities for prevention. She was also the GOG/NRG Study Chair of the NCI-CTEP sponsored GOG9929, a phase 1 study of sequential ipilimumab after definitive chemoradiation for patients with newly diagnosed high-risk locally advanced cervical cancer. She received her SB from MIT, her MS in epidemiology from Harvard School of Public Health, and her MD from UC Irvine. She completed Ob-Gyn residency at the Beth Israel Deaconess Medical Center in Boston, then gynecologic oncology fellowship at the M.D. Anderson Cancer Center. Yvonne is a long-time supporter of the Pasadena Humane Society since adopting Sally, her Belgium Malinois from there in 2011. In her spare time, Yvonne enjoys snowboarding, spinning, and yoga.

Eric Risser

Eric Risser
SVP, Chief Business Officer
Macrogenics
Eric Risser
SVP, Chief Business Officer
Macrogenics
 
About Speaker:

Eric Risser has over 20 years of business development, strategy and portfolio management experience across both small biotechnology and large pharmaceutical companies. During his career, he has led multiple major transactions in the pharmaceuticals area, including company acquisitions, divestments, equity financings, product licenses and research collaborations. He currently leads the business development, program management and new product planning functions at MacroGenics, and was responsible for the execution of MacroGenics’ partnerships with Janssen, Takeda, Gilead, Servier, Pfizer and Boehringer Ingelheim. Prior to joining MacroGenics, he served as Executive Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures and as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

Kevin Webster

Kevin Webster
Sr. Vice President, Cancer Biology
eFFECTOR Therapeutics
Kevin Webster
Sr. Vice President, Cancer Biology
eFFECTOR Therapeutics
 
About Speaker:

Dr. Webster is Sr. Vice President of Cancer Biology at eFFECTOR Therapeutics focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Prior to joining eFFECTOR Dr. Webster was Vice President of Oncology Research at AstraZeneca Pharmaceuticals, where he led the oncology discovery organization in Waltham, MA. In this role he served on the global oncology leadership team accountable for science strategy overseeing the delivery of a project portfolio spanning discovery and early clinical development. During his tenure with AstraZeneca he was accountable for building a new drug discovery bioscience organization in the US, as well as spearheading the creation of novel partnerships with academia and biotech organizations. Prior to AstraZeneca, Dr. Webster served as a member of the oncology drug discovery leadership team at Bristol Myers Squibb where he led the cell cycle and apoptosis research areas and delivered multiple discovery research projects from inception through early clinical development. Dr. Webster holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University where he studied protein-RNA interactions and translational regulation.

Complementary & Companion Diagnostics in Oncology 2017
DISTINGUISHED SPEAKERS
Luigi Catanzariti

Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
 
About Speaker:

Luigi Catanzariti, Ph.D., is the founder and principal of Catanzariti & Associates, a Boston-based private group specializing in technical, regulatory and strategic consulting services in the emerging field of precision medicine, oncology biomarkers, and companion diagnostics. From 2009-2016 he was an Executive Director at NOVARTIS oncology in Cambridge, Massachusetts. In this role, he was responsible for the integrated companion diagnostic strategy/execution of various oncology drug development programs (Ceritinib/Zykadia, Mekinist-Tafinlar, Sonidegib - among others). Zykadia/Ceritinib obtained in 2017 first-line approval (FDA/EMEA) in NSCLC based on a patient selection strategy implemented for the  ASCEND-4 trial.  Before, he held key executive roles at IPSEN (Paris), PYROSEQUENCING (Boston) and bioMerieux (Lyon). He is also author/co-author of numerous international diagnostic and biomarker patents.

Chetan Deshpande

Chetan Deshpande
Senior Manager-Biomarker Assay Specialist
Pfizer
Chetan Deshpande
Senior Manager-Biomarker Assay Specialist
Pfizer
 
About Speaker:
Paul Insel

Paul Insel
Distinguished Professor, Depts. of Medicine and Pharmacology
University of California, San Diego
Paul Insel
Distinguished Professor, Depts. of Medicine and Pharmacology
University of California, San Diego
 
About Speaker:

Dr. Insel received his M.D. from the University of Michigan, clinical training at Boston City Hospital (Harvard Medical Service), and research training at NIH and UC San Francisco (UCSF). He joined the UCSF faculty and llater relocated to UC San Diego (UCSD), where he is Distinguished Professor of Pharmacology and Medicine and Co-Director of the Medical Scientist (MD/PhD) Training Program. Dr. Insel’s research efforts focus on G-protein-coupled receptors (GPCRs) and include studies of GPCR expression, G-proteins, G-protein-regulated effectors, and signaling compartmentation in lipid rafts/caveolae. Dr. Insel has published >280 original articles and 160 invited articles/reviews. He has served as Editor-in-Chief of numerous scientific journals, including the Journal of Clinical Investigation, Molecular Pharmacology, and American Journal of Physiology-Cell Physiology. Currently, he is Editor, Annual Review of Pharmacology and Toxicology; Senior Editor, British Journal of Pharmacology and co-Head of Faculty, Faculty of 1000Prime in Pharmacology and Drug Discovery. Dr. Insel holds a Doc. Hon Causa from the University of Paris, is a Fellow, American Association for the Advancement of Science and has received awards from the American Physiological Society, Dutch Pharmacology Society and American Society for Pharmacology and Experimental Therapeutics.

Eric Lindquist

Eric Lindquist
Vice President of Pharma Business Development
Natera
Eric Lindquist
Vice President of Pharma Business Development
Natera
 
About Speaker:

Eric has over 20 years of experience in the precision medicine space. Eric was trained in cytogenetics but started his commercial career at Abbott Molecular selling the first DNA based FDA approved and cleared companion diagnostic assays to directly to laboratories and clinicians.  Eric has also worked for Johnson and Johnson in their Veridex group enabling pharmaceutical companies to incorporate rare cells into their clinical trials. Eric then worked at Roche where he executed a number of public and non-public companion diagnostic agreements.  Eric also led the Translational Diagnostics team at Asuragen.  While at Asuragen, Eric’s team executed an umbrella agreement with lllumina enabling Asuragen to be the first 3rd party company to have CDx developed FTO on the MiSeq platform.   Eric has also consulted for a significant number of diagnostic and pharmaceutical regarding their companion diagnostic partnership, development, and commercialization strategies and tactics.

Kamala Maddali

Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
About Speaker:

Dr. Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc. In addition, Dr. Maddali is the Vice Chair of the Philadelphia Chapter of Women in Bio. She is also a Scientific Advisory Member for International Cancer Advocacy Network. Her background includes time at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics. Dr. Maddali holds a Ph.D. in Pharmacology from University of Missouri-Columbia and a DVM from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali loves to travel with her family which includes her husband, Vamsi and son, Venkat. She enjoys music and watching cartoons at her leisure and engaging in many non-profit activities to create cancer awareness.

Saikat Nandi

Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
About Speaker:

Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercialization Hub (REACH) facilities in the nation. Dr. Nandi also serves as an advisor to Salus Discovery, a start-up from the University of Wisconsin-Madison and Program Director for GTCbio Cancer Therapeutics and Partnering Summit. Dr. Nandi has over 10 years of experience in oncology and drug discovery and over 4 years of experience in technology commercialization and business development through his involvement in the organizations and financially successful start-up companies. Dr. Nandi received his D.Phil. (PhD) from Oxford University and has served as an Editor and Reviewer for over a dozen international scientific journals.

Rita Shaknovich

Rita Shaknovich
CMO
Cancer Genetics Inc
Rita Shaknovich
CMO
Cancer Genetics Inc
 
About Speaker:

I am a physician scientist with strong interests in cancer biology and translational research. My clinical expertise is in Hematopathology with the focus on Hematologic malignancies. My research training was focused on cancer in general and on hematologic malignancies in particular from the time of my PhD, investigating function of PLZF-RAR fusion protein in Acute Promyelocytic Leukemia. I have extensive experience in human and mouse pathology, assessment of mouse cancer models, experimental hematology and immunology. My laboratory in WCMC focused on epigenetics of normal B cell development and lymphomagenesis. We utilized cell lines, primary lymphomas and mouse models to investigate epigenetic changes that take place during B cell ontogeny and neoplastic transformation of normal B cells into lymphomas. We successfully utilized many experimental and computational tools that allow genome-wide profiling of DNA methylation and gene expression, like ERRBS, CHIP-seq, RNA-seq, exome and whole genome sequencing among many others. My current role as a Chief Medical Officer at Cancer Genetics Inc is to identify areas of greatest unmet need in cancer diagnostics, to adopt newest technologies and to develop novel tools that would address those needs. We collaborate with leading national and international researchers and institutions to accomplish these goals.